Clinical Trial

Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis

Name: Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis — clinical trial record (NCT06971380)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

A Phase II study of HBI0101 (NXC-201) BCMA-CART in Multiple Myeloma and Light-chain Amyloidosis Patients. The goal of the study is to evaluate the efficacy and safety of HBI0101 CART.

Trial Details

NCT Number	NCT06971380
Lead Sponsor	Polina Stepensky
Conditions	Multiple Myeloma, Refractory to Standard Treatment, Multiple Myeloma, Relapsed, Light Chain Amyloidosis
Enrollment	180 participants
Start Date	2025-03-01
Primary Completion	2028-05-15 (estimated)
Study Completion	2030-05-15 (estimated)
Updated on ClinicalTrials.gov	2025-05-14